BRAF and mucosal melanoma: Treatment with immune checkpoint inhibitors (pembrolizumab, nivolumab, ipilimumab) resulted in a significant improvement in recurrence free survival in patients with surgically excised stage III/IV cutaneous melanoma; targeted therapy with a combination of dabrafenib and trametinib is another option when melanoma harbors V600 BRAF mutation, but the use of adjuvant therapy in the treatment of mucosal melanoma is underexplored [24].